How did Avalo Therapeutics' revenue and expenses shift in Q4 2024 compared to previous quarters?

Avalo Therapeutics experienced a significant decline in net income in Q4 2024 compared to the previous quarter, Q3 2024, but showed no change in total revenue over the same period. 1. **Revenue Stability**: The total revenue for Q4 2024 was $192,000, which is the same as the revenue reported for Q3 2024. This indicates that the company's revenue stream remained stable during this period. |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |AVTX|AVTX.O|Avalo Therapeutics|2024 Q1||0|186| |AVTX|AVTX.O|Avalo Therapeutics|2024 Q3||249000|186| |AVTX|AVTX.O|Avalo Therapeutics|2024 Q4|-66.37478108581436|192000|186| 2. **Net Income Decline**: However, the net income for Q4 2024 was -$35.34 million, while for Q3 2024, it was $23.04 million. This represents a substantial decrease in profitability, which could be indicative of increased expenses or reduced profitability in Q4 2024. |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |AVTX|AVTX.O|Avalo Therapeutics|2023 Q4|16.754993885038726|-8168000|186| |AVTX|AVTX.O|Avalo Therapeutics|2024 Q1|-1118.3827222501257|-1.2129E8|186| |AVTX|AVTX.O|Avalo Therapeutics|2024 Q2|1301.7942145734164|9.8463E7|186| |AVTX|AVTX.O|Avalo Therapeutics|2024 Q3|540.646518745218|2.3037E7|186| In summary, Avalo Therapeutics saw no change in revenue but a significant drop in net income in Q4 2024 compared to Q3 2024, suggesting that the company's expenses may have increased or its profitability may have decreased during this period.